Actuate Therapeutics, Inc

Actuate is headquartered in the United States and operates as a development-stage biotech with outsourced manufacturing and clinical operations. A key geographic exposure is its reliance on a single drug substance manufacturer located in China for elraglusib, creating sensitivity to U.S.–China trade policy, tariffs, and supply continuity. Clinical development and regulatory interactions are primarily oriented toward the U.S. market, with potential expansion to additional jurisdictions depending on trial strategy and funding. Because the company has no product revenue, reported results are driven more by where costs are incurred and where critical suppliers are located than by end-market sales mix.

Actuate’s core risk is clinical and regulatory: elraglusib may fail to demonstrate sufficient safety/efficacy, or regulators may require additional studies that increase cost and timelines. Liquidity risk is acute; the company disclosed substantial doubt about its ability to continue as a going concern and indicated existing cash may not fund operations beyond the second quarter of fiscal year 2025, which could force program delays or cessation. The business also has concentrated supply-chain risk because it relies on a single China-based manufacturer for elraglusib drug substance, exposing it to tariffs, trade restrictions, and disruption. Like other clinical-stage biotechs, it faces IP protection risk, dependence on third parties (CROs/CMOs), and future commercialization risks including market acceptance and reimbursement if approval is achieved.